- Home
- PBYI vs MCRB Comparison
PBYI vs MCRB Comparison
Compare PBYI & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- MCRB
- Stock Information
- Founded
- PBYI 2010
- MCRB 2010
- Country
- PBYI United States
- MCRB United States
- Employees
- PBYI N/A
- MCRB N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- PBYI Health Care
- MCRB Health Care
- Exchange
- PBYI Nasdaq
- MCRB Nasdaq
- Market Cap
- PBYI 171.7M
- MCRB 165.3M
- IPO Year
- PBYI N/A
- MCRB 2015
- Fundamental
- Price
- PBYI $4.56
- MCRB $22.85
- Analyst Decision
- PBYI Strong Buy
- MCRB Hold
- Analyst Count
- PBYI 1
- MCRB 4
- Target Price
- PBYI $7.00
- MCRB $73.67
- AVG Volume (30 Days)
- PBYI 980.5K
- MCRB 155.7K
- Earning Date
- PBYI 11-06-2025
- MCRB 08-06-2025
- Dividend Yield
- PBYI N/A
- MCRB N/A
- EPS Growth
- PBYI 434.29
- MCRB N/A
- EPS
- PBYI 0.97
- MCRB 10.22
- Revenue
- PBYI $238,062,000.00
- MCRB N/A
- Revenue This Year
- PBYI N/A
- MCRB N/A
- Revenue Next Year
- PBYI N/A
- MCRB N/A
- P/E Ratio
- PBYI $4.75
- MCRB $2.24
- Revenue Growth
- PBYI 8.63
- MCRB N/A
- 52 Week Low
- PBYI $2.25
- MCRB $6.53
- 52 Week High
- PBYI $6.07
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- PBYI 47.28
- MCRB 74.75
- Support Level
- PBYI $4.93
- MCRB $17.82
- Resistance Level
- PBYI $5.22
- MCRB $19.87
- Average True Range (ATR)
- PBYI 0.32
- MCRB 1.43
- MACD
- PBYI -0.10
- MCRB 0.12
- Stochastic Oscillator
- PBYI 7.37
- MCRB 78.43
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.